My watch list  

506 Current news from Canada


You can refine your search further. Select from the filter options on the left to narrow down your results.

Enobia Pharma initiates clinical testing of Enzyme Replacement Therapy to treat hypophosphatasia


Enobia Pharma announced that the first patient in its clinical program for hypophosphatasia has been dosed. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this genetic bone disorder for which there is no approved treatment. Under two separate ...


Victhom's Neurobionix business unit achieves ISO 13485:2003 certification


Victhom Human Bionics Inc., announced that its Neurobionix business unit has obtained ISO 13485:2003 certification for its Quality Management System to manufacture medical devices. This certification, an internationally recognized management system standard developed by the International ...


Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well


Bioniche Life Sciences Inc. announced that its first Phase III clinical trial with a formulation of Mycobacterial Cell Wall-DNA Complex (MCC), trademarked Urocidin, for the treatment of bladder cancer, is progressing well. The Data Safety Monitoring Committee held its fifth scheduled meeting ...


MedMira Reaches Funding Agreement to Enable US Market Expansion


MedMira Inc. announced that it has entered in to an agreement in principal with an investor for the issuance of a CDN $650,000 convertible debenture. Under the terms of the agreement, the debenture will bear interest of 9% per annum and will mature four years from the date of close. The ...


image description
Dr. Stewart Sell Wins ISOBM-Abbott Award


Dr. Stewart Sell, a member of BioCurex's Scientific Advisory Board, has been awarded the prestigious ISOBM-Abbott award for his lifetime achievements in cancer research, immunology, developmental biology, and stem cell research. Dr. Sell's achievements go beyond research, since he is an excellent ...


Painceptor Pharma gains patent for lead drug


PainCeptor Pharma Corp., a biopharmaceutical company focused on the development of novel therapeutics for the treatment of chronic and acute pain, announced that it has been awarded a series of milestone patents for its two lead drug development programs, NGF (nerve growth factor) and ASIC (acid ...


Page 51 From 51
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE